Table 7 Prophylactic administration and adverse drug reactions to G-CSFs
Q20. Regarding the use of pegfilgrastim during 2-week interval chemotherapy, what kind of suggestion do you do? (N = 164) | |
Use pegfilgrastim on the day of chemotherapy | 2 (1.2) |
Use pegfilgrastim on the following day of chemotherapy | 93 (56.7) |
Use pegfilgrastim on the following day of chemotherapy. I administer chemotherapy one day later of the next cycle, and use pegfilgrastim on the following day of chemotherapy | 8 (4.9) |
Do not use pegfilgrastim | 61 (37.2) |
Q21.What explanation or suggestion do you provide for bone pain, an adverse drug reaction, in the use of G-CSFs? (N = 187) | |
Do not explain about adverse events of G-CSFs to a patient | 34 (18.2) |
Have a medical examination in the occurrence of bone pain | 67 (35.8) |
Prescribe oral NSAIDs in advance of the occurrence of bone pain | 85 (45.5) |
Prescribe oral antihistaminic drugs in advance in the occurrence of bone pain | 1 (0.5) |
Q22. Are G-CSFs used as primary prophylaxis at your institute? (N = 293) | |
We used G-CSFs only during chemotherapy aimed at the symptom palliation | 39 (13.3) |
We used G-CSFs only during chemotherapy aimed at achieving a cure or prolonging survival time | 162 (55.3) |
We do not use G-CSFs as primary prophylaxis | 92 (31.4) |